{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T21:02:57Z","timestamp":1784408577372,"version":"3.55.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clim.2024.110214","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T16:20:04Z","timestamp":1712679604000},"page":"110214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Defining remission in childhood-onset lupus: PReS-endorsed consensus definitions by an international task force"],"prefix":"10.1016","volume":"263","author":[{"given":"E.M.D.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ainsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Al-Abadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Avcin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bortey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Burnham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ciurtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.","family":"Hedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kamphuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Morand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"\u00d6zen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.","family":"Pain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ravelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Saad Magalhaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pilkington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Schonenberg-Meinema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Tullus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.W.","family":"Beresford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Goilav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Goss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Oni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.D.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2024.110214_bb0005","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/art.23204","article-title":"Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus","volume":"58","author":"Brunner","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2024.110214_bb0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.24091","article-title":"Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus","volume":"61","author":"Hersh","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2024.110214_bb0015","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.rdc.2009.12.012","article-title":"Pediatric lupus-are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?","volume":"36","author":"Mina","year":"2010","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.clim.2024.110214_bb0020","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/0961203307087875","article-title":"Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII)","volume":"17","author":"Tucker","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.clim.2024.110214_bb0025","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/art.40697","article-title":"Long-term clinical outcomes in a cohort of adults with childhood-onset systemic lupus erythematosus","volume":"71","author":"Groot","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.clim.2024.110214_bb0030","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.21955","article-title":"Mortality in systemic lupus erythematosus","volume":"54","author":"Bernatsky","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2024.110214_bb0035","doi-asserted-by":"crossref","DOI":"10.1177\/0961203316644333","article-title":"Differences in disease phenotype and severity in SLE across age groups","author":"Ambrose","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.clim.2024.110214_bb0040","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.4070\/kcj.2019.0261","article-title":"Ideal target blood pressure in hypertension","volume":"49","author":"Park","year":"2019","journal-title":"Korean Circ. J."},{"key":"10.1016\/j.clim.2024.110214_bb0045","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(94)91405-2","article-title":"Pharmacological treatment of hypertension","volume":"344","author":"Swales","year":"1994","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.clim.2024.110214_bb0050","article-title":"The impact of cardiovascular disease on people with diabetes: the potential for prevention","volume":"350","author":"Eastman","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2024.110214_bb0055","doi-asserted-by":"crossref","first-page":"166","DOI":"10.4103\/2230-8210.129106","article-title":"Treat-to-target trials in diabetes","volume":"18","author":"Wangnoo","year":"2014","journal-title":"Indian J. Endocrinol. Metab."},{"key":"10.1016\/j.clim.2024.110214_bb0060","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2024.110214_bb0065","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41584-021-00739-3","article-title":"Treat-to-target in systemic lupus erythematosus: advancing towards its implementation","volume":"18","author":"Parra Sanchez","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.clim.2024.110214_bb0070","article-title":"Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus","author":"Smith","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.clim.2024.110214_bb0075","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keab173","article-title":"\u201cIt is good to have a target in mind\u201d: qualitative views of patients and parents informing a treat to target clinical trial in JSLE","author":"Smith","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.clim.2024.110214_bb0080","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000571","article-title":"LLDAS is an attainable treat-to-target goal in childhood-onset SLE","volume":"8","author":"Wahadat","year":"2021","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.clim.2024.110214_bb0085","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1177\/09612033211054399","article-title":"Low disease activity state in juvenile-onset systemic lupus erythematosus","volume":"30","author":"Ozturk","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.clim.2024.110214_bb0090","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s41927-022-00300-z","article-title":"Improving communication of the concept of \u2018treat-to target\u2019 in childhood lupus: a public and patient (PPI) engagement project involving children and young people","volume":"6","author":"Elliott","year":"2022","journal-title":"BMC Rheumatol."},{"key":"10.1016\/j.clim.2024.110214_bb0095","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1016\/S2665-9913(22)00106-0","article-title":"Research priority setting for paediatric rheumatology in the UK","volume":"4","author":"Smith","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.clim.2024.110214_bb0100","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2024.110214_bb0105","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2665-9913(19)30105-5","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study","volume":"2","author":"Apostolopoulos","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.clim.2024.110214_bb0110","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.semarthrit.2018.02.014","article-title":"Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study","volume":"48","author":"Fanouriakis","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.clim.2024.110214_bb0115","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a lupus low disease activity state (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2024.110214_bb0120","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1016\/S2665-9913(19)30048-7","article-title":"Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study","volume":"1","author":"Golder","year":"2019","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.clim.2024.110214_bb0125","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/S2665-9913(19)30037-2","article-title":"Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study","volume":"1","author":"Golder","year":"2019","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.clim.2024.110214_bb0130","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/art.40571","article-title":"Comparison of remission and lupus low disease activity state in damage prevention in a United States Systemic Lupus Erythematosus Cohort","volume":"70","author":"Petri","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.clim.2024.110214_bb0135","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s13075-017-1451-5","article-title":"Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus","volume":"19","author":"Piga","year":"2017","journal-title":"Arthritis Res. Therapy"},{"key":"10.1016\/j.clim.2024.110214_bb0140","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2017-000234","article-title":"Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort","volume":"5","author":"Tani","year":"2018","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.clim.2024.110214_bb0145","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/rheumatology\/kew377","article-title":"Both prolonged remission and lupus low disease activity state are associated with reduced damage accrual in systemic lupus erythematosus","volume":"56","author":"Tsang-A-Sjoe","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.clim.2024.110214_bb0150","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000955","article-title":"Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort","volume":"5","author":"Ugarte-Gil","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.clim.2024.110214_bb0155","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1136\/annrheumdis-2017-211814","article-title":"Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL)","volume":"76","author":"Ugarte-Gil","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2024.110214_bb0160","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/acr.24023","article-title":"Lupus low disease activity state and reduced direct health care costs in patients with systemic Lupus Erythematosus","volume":"72","author":"Yeo","year":"2020","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.clim.2024.110214_bb0165","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2022-223328","article-title":"Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to-consider from an international task force","author":"Smith","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2024.110214_bb0170","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.clim.2024.110214_bb0175","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/annrheumdis-2016-209519","article-title":"A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)","volume":"76","author":"van Vollenhoven","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2024.110214_bb0180","doi-asserted-by":"crossref","first-page":"109296","DOI":"10.1016\/j.clim.2023.109296","article-title":"PReS-endorsed international childhood lupus T2T task force definition of childhood lupus low disease activity state (cLLDAS)","volume":"250","author":"Smith","year":"2023","journal-title":"Clin. Immunol."},{"issue":"6","key":"10.1016\/j.clim.2024.110214_bb0185","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/ard-2022-223328","article-title":"Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to-consider from an international task force","volume":"82","author":"Smith","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2024.110214_bb0190","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.2042-7174.1996.tb00844.x","article-title":"The Delphi and nominal group techniques in health services research","volume":"4","author":"Cantrill","year":"1996","journal-title":"Int. J. Pharm. Pract."},{"key":"10.1016\/j.clim.2024.110214_bb0195","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/rheumatology\/key349","article-title":"The relationship between remission and health-related quality of life in a cohort of SLE patients","volume":"58","author":"Tsang","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.clim.2024.110214_bb0200","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/acr.24009","article-title":"Better health-related quality of life in systemic lupus erythematosus predicted by low disease activity state\/remission: data from the Peruvian Almenara Lupus Cohort","volume":"72","author":"Ugarte-Gil","year":"2020","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.clim.2024.110214_bb0205","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1177\/0961203319876998","article-title":"Remission and low disease activity state prevent hospitalizations in systemic lupus erythematosus patients","volume":"28","author":"Reategui-Sokolova","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.clim.2024.110214_bb0210","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000616","article-title":"LLDAS (lupus low disease activity state) and\/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almenara Lupus Cohort","volume":"9","author":"Ugarte-Gil","year":"2022","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.clim.2024.110214_bb0215","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/annrheumdis-2016-209489","article-title":"Remission in systemic lupus erythematosus: durable remission is rare","volume":"76","author":"Wilhelm","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2024.110214_bb0220","first-page":"72","article-title":"Impact of remission and low disease activity status on hospitalizations among SLE patients from the GLADEL Latin American cohort","author":"Pons-Estel","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.clim.2024.110214_bb0225","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/0961203319826693","article-title":"Remission and low disease activity state (LDAS) are protective of intermediate and long-term outcomes in SLE patients. Results from LUMINA (LXXVIII), a multiethnic, multicenter US cohort","volume":"28","author":"Alarcon","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.clim.2024.110214_bb0230","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1136\/annrheumdis-2020-217070","article-title":"Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort","volume":"79","author":"Saccon","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2024.110214_bb0235","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/annrheumdis-2016-210154","article-title":"The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients","volume":"76","author":"Zen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2024.110214_bb0240","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.semarthrit.2019.05.010","article-title":"Longitudinal disease- and steroid-related damage among adults with childhood-onset systemic lupus erythematosus","volume":"49","author":"Heshin-Bekenstein","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.clim.2024.110214_bb0245","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1002\/art.34410","article-title":"Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort","volume":"64","author":"Watson","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2024.110214_bb0250","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1177\/0961203318801526","article-title":"Clinical predictors of active LN development in children - evidence from the UK JSLE Cohort Study","volume":"27","author":"Smith","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.clim.2024.110214_bb0255","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/art.10072","article-title":"Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage","volume":"46","author":"Brunner","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2024.110214_bb0260","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/annrheumdis-2011-200106","article-title":"A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus","volume":"71","author":"Rygg","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2024.110214_bb0265","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2665-9913(22)00304-6","article-title":"Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study","volume":"4","author":"Kandane-Rathnayake","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.clim.2024.110214_bb0270","first-page":"1265","article-title":"Mortality studies in systemic lupus erythematosus. Results from a single center. Predictor variables for mortality","volume":"22","author":"Abu-Shakra","year":"1995","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2024.110214_bb0275","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/rheumatology\/kep062","article-title":"Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years","volume":"48","author":"Chambers","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.clim.2024.110214_bb0280","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/acr.23867","article-title":"Association of achieving lupus low disease activity state fifty percent of the time with both reduced damage accrual and mortality in patients with systemic lupus erythematosus","volume":"72","author":"Sharma","year":"2020","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.clim.2024.110214_bb0285","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.semarthrit.2018.09.005","article-title":"Relationship between damage and mortality in juvenile-onset systemic lupus erythematosus: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER)","volume":"48","author":"Torrente-Segarra","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.clim.2024.110214_bb0290","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","author":"Fanouriakis","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2024.110214_bb0295","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/BOR.0000000000000913","article-title":"Current views on lupus in children","volume":"35","author":"Smith","year":"2023","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.clim.2024.110214_bb0300","doi-asserted-by":"crossref","first-page":"109028","DOI":"10.1016\/j.clim.2022.109028","article-title":"Real world treatment of juvenile-onset systemic lupus erythematosus: Data from the UK JSLE cohort study","author":"Smith","year":"2022","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2024.110214_bb0305","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.semarthrit.2018.01.001","article-title":"Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus","volume":"48","author":"Oon","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.clim.2024.110214_bb0310","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1002\/art.39682","article-title":"Cumulative corticosteroid dose over fifty-two weeks in patients with systemic lupus erythematosus: pooled analyses from the phase III belimumab trials","volume":"68","author":"van Vollenhoven","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.clim.2024.110214_bb0315","doi-asserted-by":"crossref","first-page":"e584","DOI":"10.1016\/S2665-9913(23)00209-6","article-title":"Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study","volume":"5","author":"Cho","year":"2023","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.clim.2024.110214_bb0320","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1093\/rheumatology\/keaa383","article-title":"Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties","volume":"59","author":"Chessa","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.clim.2024.110214_bb0325","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1016\/S2665-9913(22)00107-2","article-title":"Physician global assessment international standardisation COnsensus in systemic lupus erythematosus: the PISCOS study","volume":"4","author":"Piga","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.clim.2024.110214_bb0330","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kead460","article-title":"Defining the physician global assessment threshold equivalent to remission in patients with systemic lupus erythematosus","author":"Mucke","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.clim.2024.110214_bb0335","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1191\/0961203306lu2316oa","article-title":"Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus","volume":"15","author":"Bandeira","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.clim.2024.110214_bb0340","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2019-216303","article-title":"Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial","volume":"79","author":"Mathian","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.clim.2024.110214_bb0345","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1177\/09612033211002269","article-title":"Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study","volume":"30","author":"Fasano","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.clim.2024.110214_bb0350","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000916","article-title":"Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience","volume":"5","author":"Tani","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.clim.2024.110214_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152068","article-title":"The pediatric glucocorticoid toxicity index","volume":"56","author":"Brogan","year":"2022","journal-title":"Semin. Arthritis Rheum."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661624001050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661624001050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T19:43:46Z","timestamp":1715975026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661624001050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":71,"alternative-id":["S1521661624001050"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2024.110214","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Defining remission in childhood-onset lupus: PReS-endorsed consensus definitions by an international task force","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2024.110214","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110214"}}